Status:
COMPLETED
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multipl...
Eligibility Criteria
Inclusion
- Male and female participants who are overtly healthy as determined by medical evaluation (Part A)
- Participants with T2DM diagnosed greater than 1 year before enrollment (Part A and Part B)
- Have a body mass index within the range of 18.5 to less than or equal to (\<=) 32 kilograms per square meter (kg/m²) for healthy participants and 18.5 to 40 kg/m² for T2DM participants.
- Male or female participants of nonchildbearing potential
Exclusion
- Have proliferative retinopathy or maculopathy and/or severe neuropathy
- Have been treated with sulfonylurea, thiazolidinedione, alpha-glucosidase inhibitor, glucagon-like peptide-1 receptor agonist or Insulin within the previous 3 months
- Have received chronic systemic glucocorticoid therapy in the past 3 months
- Are currently enrolled in another clinical study trial involving medical research, or have participated within the last 30 days in a clinical study involving an investigational product.
Key Trial Info
Start Date :
November 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2024
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT06132126
Start Date
November 17 2023
End Date
June 28 2024
Last Update
July 24 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CenExel ACT
Anaheim, California, United States, 92801
2
Qps-Mra, Llc
Miami, Florida, United States, 33143
3
Labcorp CRU
Dallas, Texas, United States, 75247